Lannett Co Inc (NYSE:LCI) has been assigned a consensus rating of “Hold” from the eight ratings firms that are covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, four have given a hold rating and three have assigned a buy rating to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $21.00.

Several equities research analysts have commented on the company. BidaskClub downgraded Lannett Co from a “sell” rating to a “strong sell” rating in a report on Tuesday, August 8th. Oppenheimer Holdings, Inc. reissued a “hold” rating on shares of Lannett Co in a report on Wednesday, August 23rd. Deutsche Bank AG dropped their target price on Lannett Co from $23.00 to $19.00 and set a “hold” rating on the stock in a report on Monday, August 14th. Zacks Investment Research raised Lannett Co from a “sell” rating to a “hold” rating in a report on Tuesday, October 24th. Finally, ValuEngine raised Lannett Co from a “hold” rating to a “buy” rating in a report on Monday, October 2nd.

Lannett Co (NYSE:LCI) last released its quarterly earnings results on Wednesday, August 23rd. The company reported $0.40 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.40. Lannett Co had a positive return on equity of 19.80% and a negative net margin of 0.09%. The company had revenue of $139.10 million for the quarter, compared to analyst estimates of $139.01 million. During the same period in the previous year, the company posted $0.73 earnings per share. The firm’s revenue was down 17.6% on a year-over-year basis.

A number of institutional investors have recently added to or reduced their stakes in LCI. Arizona State Retirement System raised its stake in shares of Lannett Co by 0.7% in the second quarter. Arizona State Retirement System now owns 15,362 shares of the company’s stock worth $313,000 after purchasing an additional 100 shares during the last quarter. CS Mckee LP raised its stake in shares of Lannett Co by 0.6% in the second quarter. CS Mckee LP now owns 35,400 shares of the company’s stock worth $722,000 after purchasing an additional 200 shares during the last quarter. Texas Permanent School Fund raised its stake in shares of Lannett Co by 1.0% in the second quarter. Texas Permanent School Fund now owns 21,474 shares of the company’s stock worth $438,000 after purchasing an additional 203 shares during the last quarter. Rhumbline Advisers raised its stake in shares of Lannett Co by 0.4% in the second quarter. Rhumbline Advisers now owns 61,600 shares of the company’s stock worth $1,257,000 after purchasing an additional 244 shares during the last quarter. Finally, The Manufacturers Life Insurance Company raised its stake in shares of Lannett Co by 1.3% in the second quarter. The Manufacturers Life Insurance Company now owns 22,366 shares of the company’s stock worth $456,000 after purchasing an additional 297 shares during the last quarter. 88.23% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: This story was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this story on another domain, it was illegally copied and republished in violation of United States and international copyright & trademark law. The legal version of this story can be accessed at https://www.americanbankingnews.com/2017/11/01/lannett-co-inc-lci-given-consensus-recommendation-of-hold-by-analysts.html.

About Lannett Co

Lannett Company, Inc develops, manufactures, markets and distributes generic versions of brand pharmaceutical products. The Company manufactures and/or distributes prescription products with the exception of a small portfolio of over-the-counter products manufactured by its subsidiary, Silarx Pharmaceuticals, Inc As of June 30, 2016, the Company’s products included Acetazolamide Tablets; Butalbital, Acetaminophen and Caffeine Tablets; Butalbital, Aspirin and Caffeine Capsules; C-Topical Solution; Digoxin Tablets; Glycolax Rx; Isosorbide Mononitrate CR; Levothyroxine Sodium Tablets; Methylphenidate HCL CD; Methylphenidate ER; Nifedipine CR; Omeprazole DR; Oxbutynin ER; Pantoprazole DR; Pilocarpine HCl Tablets; Triamterene w/Hydrochlorothiazide Capsules, and Ursodiol Capsules.

Analyst Recommendations for Lannett Co (NYSE:LCI)

Receive News & Ratings for Lannett Co Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lannett Co Inc and related companies with MarketBeat.com's FREE daily email newsletter.